WHO vaccine-preventable diseases: monitoring system. 2020 global summary

Last updated 15-July-2020 (data as of 12-October-2020)
Next overall update End 2020

Select a country


Development status:	Developed economy	GNI / capita (US$):	47'350¹	Infant (under 12 months) mortality rate:	3²
Development status:	Developed economy	GDP / capita (US$):	54'545¹	Child (under 5 years) mortality rate:	4²

					2019	2018	2017	2016	2015	2000	1990	1980

Population data in thousands³
Total population					11'539	11'482	11'420	11'354	11'288	10'282	10'007	9'869
Births					124	125	125	125	126	114	120	119
Surviving infants					124	124	125	125	125	113	119	118
Pop. less than 5 years					636	637	638	641	645	576	590	600
Pop. less than 15 years					1'968	1'958	1'946	1'932	1'919	1'806	1'794	1'988
Female 15-49 years					2'487	2'494	2'501	2'509	2'515	2'458	2'460	2'390

Number of reported cases							(Click for retrospective incidence data for Belgium)
Diphtheria					6	2	3	6	2	_	0	1
Japanese encephalitis					_	_	_	_	0	_	_	_
Measles***					480	117	367	_	47	_	_	_
Mumps					234	230	183	153	163	_	_	_
Pertussis					1'098	1'354	1'535	2'105	1'203	_	_	_
Polio*					0	0	0	0	0	0	0	1
Rubella***					1	1	1	1	_	_	_	_
Rubella (CRS)					0	0	0	0	0	_	_	_
Tetanus (neonatal)					_	_	0	_	_	_	0	_
Tetanus (total)**					0	0	_	_	_	_	2	4
Yellow fever					0	0	0	_	0	_	_	_
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]). Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system. * For 2019, if a country did not submit a joint reporting form, measles and rubella cases were sourced from data reported through the monthly surveillance data available from: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/

Percentage target population vaccinated by antigen							Hovering over an antigen reveals its fuller definition
	Most recent coverage survey⁴					Official country estimates⁵
							(Click for retrospective coverage estimates data for Belgium)
Vaccine	year	result	method	% card seen
BCG					_	_	_	_	_	_	_	_
DTP1					99	99	99	99	99*	97	_	_
DTP3					98	98	98	98	99	95	93	_
IPV1					99*	99*	99*	99*	99*	_	_	_
HepB_BD					_	_	_	_	_	_	_	_
HepB3					97	97	97	97	98	60	_	_
Hib3					97	97	97	97	98	86	_	_
JapEnc					_	_	_	_	_	_	_	_
MCV1					96	96	96	96	96	82	85	_
MCV2					85	85	85	85	85	_	_	_
MenA					_	_	_	_	_	_	_	_
PCV1					98	98	98	98	98	_	_	_
PCV2					97	97	97	97	98	_	_	_
PCV3					94	94	94	94	94	_	_	_
Pol3					98	98	98	98	99	96	95	_
Rota1					91	90	90	90	91	_	_	_
RotaC					87	87	87	87	88	_	_	_
RCV1					96	96	96	96	96	_	_	_
TT2plus					_	_	_	_	_	_	_	_
PAB					_	_	_	_	_	_	_	_
VAD1					_	_	_	_	_	_	_	_
YFV					_	_	_	_	_	_	_	_
* indicates the country reported above 100% coverage.

			Next update: Mid July 2021			WHO-UNICEF estimates⁶
							(Click for full retrospective WHO-UNICEF coverage estimates data for Belgium)
DTP1					99	99	99	99	99	97	97	98
DTP3					98	98	98	98	99	95	93	95
HepB3					97	97	97	97	98	60	_	_
HepB_BD					_	_	_	_	_	_	_	_
Hib3					97	97	97	97	98	86	_	_
IPV1					99	99	99	99	99	_	_	_
MCV1					96	96	96	96	96	82	85	_
MCV2					85	85	85	85	85	_	_	_
PCV3					94	94	94	94	94	_	_	_
Pol3					98	98	98	98	99	96	95	99
RCV1					96	96	96	96	96	82	85	_
RotaC					87	87	87	87	88	_	_	_

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country	43	Proportion of districts reporting DTP3 coverage:
% of coverage reports received at national level vs number of reports expected

/ \| \| \
	Greater or equal to 90%
	From 80 to 89%
	From 50 to 79%
	Less than 50%
Proportion of districts not reporting DTP3 coverage		100

Vaccine	Schedule	Entire country	Comment

Immunization Schedule^{(2019 or latest available)}		Hovering over an antigen reveals its fuller definition
DTaPHibHepBIPV	8, 12, 16 weeks; 15 months;	Yes
DTaPIPV	5-6 years;	Yes	Y5-Y6 in Wallonia, Y6 in Flanders
HepB_Adult	<18 years;	Yes	catch up vaccination <18 years: <11 years x3 half dose, 11-15 years x2 doses, 15-18 years x3 doses
HepB_Pediatric	birth;	Yes	can be administered to newborns of HBsAg+ mothers (half an adult dose)
HPV	12-14 years; +6 months;	Yes	females until August 2019, females and males from September 2019; 1st year of secondary school (Y12) in Flanders - x2 doses; 2nd year of secondary school (Y13-Y14) in Wallonia - x2 doses
Influenza_Adult	>65 years;	Yes	and adults with chronic conditions, pregnant women, healthcare workers, residents living in long-term care facilities
Influenza_Pediatric	>6 months;	Yes	children with chronic conditions
IPV	<18 months;	Yes	x3 doses with 1 month interval for <18 months with no hexavalent vaccination; and for asylumseekers asap upon arrival (<5 months normal schedule, >5 months catch-up schedule, adults x1 booster)
MenC_conj	15 months;	Yes
MMR	12 months; 10-12 years;	Yes	2nd dose at Y11-Y12 in Wallonia and at Y10 in Flanders
Pneumo_conj	8, 16 weeks; 12 months;	Yes	13-valent since July 2019 in Flanders, and since September 2019 in Brussels and Wallonia
Rotavirus	8, 12 weeks;	Yes	and 3rd dose at W16 is recommened; not included in the routine immunization program offered by health authorities
Tdap	Y14-Y16;	Yes	Y14 in Flanders and Y15-Y16 in Wallonia; and for pregnant women at each pregnancy, and cocoon strategy; +Y10 (x5 doses) boosters in adults recommended but not free (part of programme)

Indicator	Expected answer	2019	2018	2017	2016	2015	2014	2013

Immunization indicators

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization?	Yes/No/NR	Yes	Yes	Yes	No	Yes	Yes	Yes
What years does the MYP cover?	number	2012 - 2020	2012-2020	2012-2020	2012-2020		2012-2020

System performance

Total Nº districts in country	number	43	43	43		43	43	43
Nº districts with DTP3 coverage >=80%	number				0
% of districts with DTP3 coverage >=80%	From 0 to 100%
Nº districts with measles (MCV1) coverage >=95%	number
% of districts with MCV1 coverage >=95%	From 0 to 100%

Safety

Has the country a vaccine adverse events review committee?	Yes/No/NR/ND	Yes	Yes	Yes	Yes		Yes	NA
Is there a national system to monitor adverse events following immunization (AEFI)?	Yes/No/NR	Yes	Yes		Yes		Yes	Yes

Finance

% of Immunization expenditure financed, using Government funds?	From 0 to 100%

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)?	Yes/No/NR	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Sources

1 "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.

2 UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)

3 "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.

4 UNICEF/WHO survey database

5 If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.

6 WHO-UNICEF estimates.

WHO vaccine-preventable diseases: monitoring system. 2020 global summary

Select a country

Population data in thousands3

Number of reported cases

Percentage target population vaccinated by antigen

Official country estimates5

WHO-UNICEF estimates6

Immunization Schedule (2019 or latest available)

Immunization indicators

Sources

Population data in thousands³

Official country estimates⁵

WHO-UNICEF estimates⁶

Immunization Schedule^{(2019 or latest available)}